Study shows gender gap in prescriptions and treatment

Chris Carter
Chris Carter

Women are simultaneously given more drugs than men and undertreated, according to a study by Medco and the Society of Women's Health Research.

The report found that these seemingly contradictory trends are part of an overall gap in understanding how the health of women and men differs from the point of physician interaction through compliance.

“I think physicians need to know this and need to know there may be unconscious biases against managing women the same as managing men,” Dr. Chris Carter, vice president of scientific affairs at the Society for Women's Health Research, told MM&M.

Among the study's findings, based on 30 million prescription records from January through December 2010: doctors prescribed cholesterol-lowering medications for 59% of women compared with 71.5% of men, and beta-blockers were only prescribed for 63% of female heart attack patients, compared with 69% of men.

Carter said the difference in how doctors managed heart disease for women and men was a big surprise, and contributed to the study's larger message: “If you look at each of these categories and each of these metrics the women are always doing more poorly than the men,” she said.

The data did not reveal why women are falling behind on their medications or why their health is being managed differently from a physician standpoint. However, Carter said the discrepancies indicate that a shift is needed to properly address women's health.

The numbers flip, however, when looking at more superficial measures. For example, Medco found that women play excellent defense, outpacing men when it comes to colon cancer screenings, monitoring the cholesterol for which they aren't receiving medications, and for immunizations.

Carter said the society plans additional studies, but these findings could spur discussions about possible changes. “Maybe the final take home is that gender-specific treatment guidelines should be generated. Not gender-neutral,” she said.
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.